OBJECTIVES: Large-cell neuroendocrine carcinoma (LCNC) is a rare tumour characterized by aggressive biological behaviour and poor prognosis. Due to its rarity and the lack of randomized clinical trials, the best treatment is still under debate. Some recent reports indicate that adjuvant chemotherapy (CT) may have a beneficial effect on survival. Our goal was to evaluate this finding using a large series of patients with neuroendocrine tumours obtained from the European Society of Thoracic Surgeons database.
INTRODUCTION
Large-cell neuroendocrine carcinomas (LCNCs) are rare tumours that account for 2% to 3.5% of all resected primary lung cancers [1] [2] [3] . Despite a convincing body of evidence suggesting that LCNC is a high-grade neuroendocrine neoplasm, biologically related to small-cell lung carcinoma (SCLC), it is still considered a variant of large-cell carcinoma [4] and therefore treated accordingly.
Several reports reveal that the clinical behaviour and prognosis of LCNCs are similar to those of SCLCs [5] [6] [7] , with 5-year survival rates ranging from 15% to 57% [8, 9] . The rarity of LCNC makes studying its outcome in a large cohort of patients difficult; nevertheless, it has been demonstrated that an operation alone is insufficient to treat these neoplasms, even in the early stages. Adjuvant chemotherapy (CT), especially the drug combination platinum-etoposide [10, 11] , demonstrated benefits on survival and recurrence [12, 13] . Biological (e.g. somatostatin analogues) and molecular-targeted therapies (e.g. gefitinib) have been used occasionally, with encouraging results [14, 15] .
In 2012, the European Society of Thoracic Surgeons (ESTS), after launching a new working group (the Lung Neuroendocrine Tumors Working Group [NETs-WG]) designed a retrospective database through which data for more than 2050 patients with NET have been collected worldwide through December 2014. Using this unique database, we intentionally focused on LCNCs with the goal of evaluating the possible prognostic role of adjuvant CT.
MATERIALS AND METHODS
This retrospective multicentre study comprised patients with LCNC who were operated on between 1992 and 2014 at 14 thoracic surgery institutions worldwide. The end of the follow-up (FU) period was 30 January 2015. Data for all patients were derived from the ESTS lung NETS-WG retrospective data set.
Of the 2054 patients with NETs who were operated on, 460 (22.4%) presented with LCNC.
The demographic and clinicopathological characteristics of the patients included age, gender, smoking habits, previous malignancies, tumour location, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), TNM stage, the presence of vascular invasion and the administration of induction/adjuvant CT or radiotherapy (RT).
Tumours were defined as 'central' or 'peripheral' according to Detterbeck's NETs tumour location characterization: those directly visualized on bronchoscopy or in association with lung atelectasis or obstructive pneumonia were regarded as 'central', whereas those not seen on bronchoscopy were classified as 'peripheral' [16] .
All the histological samples were diagnosed by local pathologists who were experts in the field of lung/thymic NETs. All the specimens included in this study were assessed for tissue morphological characteristics and by immunohistochemical staining for lung NETs: The definitive diagnosis of LCNC was based on the 2004 WHO Lung Tumours Classification criteria [4] , as well as on Travis' histological guidelines for the diagnosis of NETs [17] . In particular, LCNC was diagnosed if the tumour had the following morphological/immunohistochemical characteristics: (i) a neuroendocrine general morphology, such as the presence of organoid nesting, palisading rosettes and trabeculae; (ii) high mitotic rates of 11 or more, (10 high-power fields); (iii) abundant necrosis (often large zones); (iv) large cell size (3 or more lymphocytes); (v) comparatively low nuclear/cytoplasm ratio; (vi) vesicular or fine chromatin; and (vii) frequent and clear nucleoli. From an immunohistochemical perspective, neuroendocrine differentiation refers to tumour cells that are positive for neuroendocrine markers, which include synaptophysin, chromogranin or CD56 (neural cell-adhesion molecule).
Surgical resections were performed through a thoracotomy (posterolateral or anterolateral) or a minimally invasive approach (video-assisted thoracoscopy); surgical procedures were defined as 'anatomical' (segmental resection, lobectomy, bilobectomy and pneumonectomy) or 'non-anatomical' (wedge resection).
Bronchoplastic (e.g. sleeve lobectomy) or enlarged procedures (e.g. chest wall or mediastinal resection) were also recorded. Lymphadenectomy was classified as 'sampling' or 'systematical/ mediastinal dissection' [18] .
The completeness of resection was categorized as R0 (absence of residual tumour), R1 (microscopic residual tumour) and R2 (macroscopic residual tumour). Local recurrence was defined as tumour relapse in the thorax or in the site of the previous surgical resection. Distant metastases were identified whenever tumour relapses occurred in other extrathoracic sites.
Tumour staging was reviewed by local pathologists: All the tumours were classified according to the AJCC Cancer Staging Manual (7th ed.) [19] .
Statistical analysis
Continuous data are presented as the median (interquartile range), whereas categorical data are presented as a number (%). Patients' characteristics were compared according to adjuvant CT administration by Mann-Whitney test for continuous variables and by v 2 test or Fisher's exact tests when the expected frequency in any cell was <5.
The primary study outcome was overall survival (OS), which was calculated from the date of the operation to the date of death of any cause. Living patients were right censored at the date they were last known to be alive. OS distribution was estimated by the Kaplan-Meier product-limit method. To account for the risk of death potentially varying between patients who had surgical resection in a given thoracic surgery institution, the effect of adjuvant therapy on OS was investigated using a gamma-distributed shared frailty Cox model, with the hospital as a random effect. To account for imbalances between groups with regard to baseline characteristics, the effect of adjuvant CT on OS was adjusted using the propensity score method and the traditional multivariable method, which included all the covariates used for the propensity score (PS) calculation. The PS for the likelihood of receiving adjuvant therapy was calculated using a logistic regression model that included 7 covariates: age (as continuous), gender, previous malignancy, ECOG-PS (0 > _ 1), vascular invasion, pTNM (tumour stages I, II and III/IV) and year of surgery (1992-99, 2000-07 and 2008-14) . The inverse probability of treatment weighting using the PS was applied to adjust the comparison [19] . The inverse probability of treatment weight (w) was calculated as follows:
where CT indicates the administration of adjuvant CT (CT = 1 indicates the presence of CT; CT = 0 indicates the absence of CT) and PS is the estimated probability of a patient receiving the adjuvant CT conditional on their baseline covariates.
In the multivariable analysis, the effect of adjuvant therapy on OS was estimated using a Cox model; along with the adjuvant therapy, all the covariates were used for the PS calculation. In the Cox models, the proportional-hazards assumption was evaluated using the Grambsch and Therneau test.
Because some patients might not have started adjuvant CT because they died early after the surgical intervention or the date that therapy was initiated was unavailable, we also performed a landmark analysis starting the second month after the operation.
A subgroup analysis was performed to evaluate whether the magnitude of the adjuvant CT effect on OS differed depending on patient characteristics.
The evaluation of the potential effect modification by subgroups was performed by including in the models an interaction term between the covariate indicating the adjuvant therapy and the subgroup covariate of interest, adjusting for all the other covariates. The significance of the interaction term suggests the non-homogeneity of the adjuvant CT effect with respect to the specific patient characteristic.
In the analysis, variables with less than 5% of values missing (ECOG-PS and pTNM) were imputed with the most frequent category [20] . For vascular invasion, we include a category indicating missing values.
In the models, age was included as a continuous variable, because we did not find evidence of a non-linear relationship with OS using a 4-knots restricted cubic spline transformation.
The statistical analysis was performed using STATA (version 11.1, StataCorp LP, TX, USA).
RESULTS

Patients' clinical characteristics
Between 1992 and 2014, 460 patients with LCNC were operated on in 14 thoracic surgery institutions worldwide. Of these, 28 patients had missing information on vital status and 32 patients on adjuvant therapy administration. Therefore, the final cohort comprised 400 patients (Fig. 1) . The median FU time was 38 months and the completeness of FU for the study was 93.6%. The clinical characteristics of the patients are summarized in Table 1 . The median age was 66 years (interquartile range 58-72); the majority of patients were men (252, 63.0%) and nonsmokers (301, 75.2%). Data concerning paraneoplastic syndromes were available for 160 patients; a total of 6 syndromes (3.8%) (1 acromegaly, 1 myasthenia gravis and 4 other syndromes) were observed.
A relatively high prevalence of previous malignancies were observed in 99 cases (24.8%). A peripheral tumour was detected in 329 patients (82.3%).
In Table 2 , we describe the prevalence of administration of adjuvant CT based on the characteristics of the analysed patients.
Surgery and multimodality treatment
The types of surgical interventions are listed in Table 3 . Resection status was available for 371 patients and R0 resection was achieved in 360 cases (97.0%, Table 1 ).
Induction therapy was offered to 53 patients (44 CT and 9 RT) and adjuvant CT was administered to 146 (36.5%). Adjuvant CT was given to 33 Stage I, 56 Stage II, 42 Stage III and 7 Stage IV patients (the stage was missing in 8 patients with adjuvant CT).
Furthermore, 38 patients (19 of whom also had postoperative CT) received adjuvant RT.
Survival and tumour recurrences
At the end of the FU period, 213 (53.3%) patients had died (n = 2 within 30 days), 69 (47.3%) in the group of those who received adjuvant CT. The most common causes of death were tumourrelated (130 cases, 61.0%), non-tumour-related (48, 22.5%) and treatment complications (5, 2.3%); in 30 cases, the cause of death was unknown.
Tumour Fig. 2A) . The 5-year OS by tumour stage was 56.4%, 42.3% and 24.8% for Stages I, II and III-IV, respectively. OS according to the administration of adjuvant CT is shown in Fig. 2B : adjusting the comparison using the PS approach, we found weak evidence of a higher OS in patients receiving adjuvant CT (adjusted hazard ratio [HR] 0.73; 95% CI: 0.56-0.96, P = 0.022). Table 4 shows the balance between the groups of variables used in the calculation of the PS before and after weighting. A nearly identical effect of adjuvant CT on OS was found when the adjustment was performed using the multivariable Cox regression model (adjusted HR 0.74; 95% CI: 0.53-1.02, P = 0.066). Variables significantly associated with poorer survival on a multivariable analysis were age (HR 1.03; 95% CI: 1.01-1.04, P = 0.001), ECOG-PS > _2 (HR 1.62; 95% CI: 1.21-2.16, P = 0.001) and advanced TNM stage (HR 2.57; 95% CI: 1.76-3.76, P < 0.001) ( Table 5 ). All variables satisfied the proportional hazard assumption.
Six patients who died within 2 months from the date of the operation had not started adjuvant CT; thus a landmark analysis starting at the beginning of postoperative month 2 showed a slight reduction of the effect of adjuvant CT on OS with an HR of 0.77 (95% CI: 0.59-1.01, P = 0.062) using the inverse probability of treatment weighting method and an HR of 0.79 (95% CI: 0.57-1.10, P = 0.167) using the traditional multivariable model adjustment.
The results of subgroup analysis are reported in Table 6 . Although the effect of adjuvant CT seems larger in some subgroups (e.g. patients with a previous malignancy with an HR of 0.56 or patients without vascular invasion with an HR of 0.65), we found no strong evidence for the heterogeneity of the effect of adjuvant CT according to patient characteristics, since no interaction term was statistically significant (Table 6 ).
DISCUSSION
LCNC is a rare tumour, with an estimated incidence among resected primary lung cancers that ranges from 2% to 3.5%, based on the recent literature. LCNC is a poorly recognized and underdiagnosed entity that is frequently mistaken for poorly differentiated non-small-cell lung cancer, atypical carcinoid and intermediate cell-type SCLC [3] . Its rarity, and therefore the lack of prospective clinical trials, makes it extremely difficult to evaluate the best treatment.
LCNC demonstrates an aggressive biological behaviour, and patients who are operated on have a significantly dismal survival rate compared with those with classic large-cell carcinoma, even in the early stage [21, 22] . In contrast, the outcome with LCNC is similar to that with SCLC. In addition, SCLC and LCNC have similar genetic changes that differentiate them from carcinoid tumours and other non-small-cell lung cancers: LCNC has cell cycle protein abnormalities (high index by Ki67 and loss of Rb and p53 tumour-suppressor genes, by mutational events) that are identical to those found with SCLC, high antiapoptotic activity and common chromosomal imbalances and genetic alterations from loss of heterozygosity [23, 24] .
It has been reported that a surgical procedure alone is not sufficient to treat LCNC, even in Stage I, because of the high risk of local recurrence/distant metastases [7, [11] [12] [13] [14] . Iyoda et al. first reported that adjuvant CT could prolong OS in Stage I LCNC [25] , and Rossi et al. confirmed the beneficial effect of platinumetoposide adjuvant CT in resected LCNCs in a retrospective study [26] . Moreover, Iyoda et al. described the results of a small prospective, non-randomized single-arm trial of an SCLC drug combination for adjuvant CT in resected LCNC, confirming the significantly beneficial effect of such treatment (5-year survival rate of 88.9% in the group receiving cisplatin-etoposide vs 47.4% in a historical cohort of patients not receiving any CT) [27] . Veronesi et al. [13] , in a large multicentre Italian retrospective study, showed a strong association between OS and induction/ adjuvant CT in Stage I LCNCs. More recently, Sarkaria et al. [10] demonstrated a trend towards an improved survival in the largest mono-institutional retrospective series of patients with LCNC who received a combination of platinum-based induction therapy and (or) adjuvant CT. Our series showed a trend towards increased administration of CT over time (Table 1) . Derived from the ESTS lung NETs-WG database, our study is, to the best of our knowledge, the largest retrospective LCNC series with 400 patients. The incidence of LCNC in our series is high compared with that previously reported, but this difference reflects the design of our database, which is completely dedicated to lung NETs. The majority of our patients are men and nonsmokers: these data are in contrast to those previously described in the literature.
We intentionally focused on the prognostic role of adjuvant CT. We were able to confirm, in a large cohort of patients, an improved survival rate in those receiving postoperative CT. In a subgroup analysis, we were, however, unable to find a particular subset of patients in whom CT might be more appropriate. Further prospective multicentre studies will help to clarify this question. In recent years, interest in the NETs multidisciplinary approach has been growing, and some clinical trials have been designed, also including lung NETs. In particular, the LUNA trial was completely dedicated to thoracic (lung and thymic) NETs: The recruitment of patients is now complete, and first results are expected in a few months.
Our study has some possible limitations due to the retrospective, multicentre design and the long recruitment period (23 years). It may also suffer from inherent treatment selection bias, which is also associated with the retrospective analysis. Moreover, the characteristics of the chemotherapeutic schedules used in the different centres for the duration of the study were not available in the data set. On the other hand, this large series, derived from worldwide multi-institutional experiences, strengthens our results.
In conclusion, we observed a trend towards benefit from adjuvant CT in patients with LCNC. Therefore, patients should be managed in a multidisciplinary setting. Although surgical procedures remain the mainstay of curative options, combinations with other treatments (e.g. neoadjuvant CT/RT) should be evaluated in future studies. The new ESTS lung NETs prospective database may in the future confirm this trend, also showing the possible role of biological drugs in this rare subset of cancers. The estimates are adjusted for all variables included in the table.
